Synthetic Biology-Driven Microbial Therapeutics for Disease Treatment

키워드

참고문헌 (102)

1. Korpela K, "Early life colonization of the human gut : microbes matter everywhere", Curr. Opin. Microbiol, 44, pp.70~78 (2018)
2. Korpela K, "Maternal fecal microbiota transplantation in cesareanborn infants rapidly restores normal gut microbial development : a proof-of-concept study", Cell, 183, pp.324~334 (2020)
3. Lloyd-Price J, "Strains, functions and dynamics in the expanded human microbiome project", Nature, 550, pp.61~66 (2017)
4. Lynch SV, "The human intestinal microbiome in health and disease", N. Engl. J. Med, 375, pp.2369~2379 (2016)
5. Fan Y, "Gut microbiota in human metabolic health and disease", Nat. Rev. Microbiol, 19, pp.55~71 (2021)
6. Selvakumar R, "Engineering living therapeutics and diagnostics : a new frontier in human health", Curr. Opin. Syst. Biol, 37, pp.100484~ (2024)
7. Kim K, "Systems and synthetic biology-driven engineering of live bacterial therapeutics", Front. Bioeng. Biotechnol, 11, pp.1267378~ (2023)
8. Pedrolli DB, "Engineering microbial living therapeutics : the synthetic biology toolbox", Trends Biotechnol, 37, pp.100~115 (2019)
9. Zhao N, "Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development", Signal. Transduct. Target. Ther, 8, pp.112~ (2023)
10. Alexander LM, "Modes of therapeutic delivery in synthetic microbiology", Trends Microbiol, 31, pp.197~211 (2023)
11. Mimee M, "Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota", Cell Syst, 1, pp.62~71 (2015)
12. Zou ZP, "Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice", Cell Host Microbe, 31, pp.199~212 (2023)
13. Steidler L, "Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10", Nat. Biotechnol, 21, pp.785~789 (2003)
14. Luo X, "Encapsulation of Escherichia coli strain Nissle 1917 in a chitosanalginate matrix by combining layer-by-layer assembly with CaCl(2)cross-linking for an effective treatment of inflammatory bowel diseases", Colloids Surf. B Biointerfaces, 189, pp.110818~ (2020)
15. Kaplan GG, "The global burden of IBD : from 2015 to 2025", Nat. Rev. Gastroenterol. Hepatol, 12, pp.720~727 (2015)
16. Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)
17. Ng SC, "Emerging trends of inflammatory bowel disease in Asia", Gastroenterol. Hepatol, 12, pp.193~196 (2016)
18. Praveschotinunt P, "Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut", Nat Commun, pp.10~ (2019)
19. Yu M, "Nononcogenic restoration of the intestinal barrier by E. coli-delivered human EGF", JCI Insight, 4, pp.e125166~ (2019)
20. Lynch JP, "Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut", Cell Host Microbe, 31, pp.634~649 (2023)
21. Steidler L, "Treatment of murine colitis by Lactococcus lactis secreting interleukin-10", Science, 289, pp.1352~1355 (2000)
22. Sasaoka T, "Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells", Am. J. Physiol. Gastrointest. Liver Physiol, 300, pp.G568~G576 (2011)
23. Zenewicz LA, "Innate and adaptive interleukin-22protects mice from inflammatory bowel disease", Immunity, 29, pp.947~957 (2008)
24. Hanson ML, "Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice", Gastroenterology, 146, pp.210~221 (2014)
25. Ortiz-Velez L, "Challenges and pitfalls in the engineering of human lnterleukin 22(hIL-22)secreting Lactobacillus reuteri", Front. Bioeng. Biotechnol, 8, pp.543~ (2020)
26. Duar RM, "Identification and characterization of intestinal lactobacilli strains capable of degrading immunotoxic peptides present in gluten", J. Appl. Microbiol, 118, pp.515~527 (2015)
27. Farrar MD, "Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin-2 in response to xylan", J. Appl. Microbiol, 98, pp.1191~1197 (2005)
28. Hamady ZZR, "Identification and use of the putative Bacteroides ovatus xylanase promoter for the inducible production of recombinant human proteins", Microbiology, 154, pp.3165~3174 (2008)
29. Hamady ZZ, "Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-beta1 under the control of dietary xylan 1", Inflamm. Bowel Dis, 17, pp.1925~1935 (2011)
30. Hamady ZZ, "Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus", Gut, 59, pp.461~469 (2010)
31. Kim TH, "Novel signal peptides and episomal plasmid system for enhanced protein secretion in engineered Bacteroides species", ACS Synth. Biol, 13, pp.648~657 (2024)
32. Liu M, "Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis", Int. Immunopharmacol, 57, pp.25~32 (2018)
33. Woo S-G, "A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing", Biosens. Bioelectron, 168, pp.112523~ (2020)
34. Sandborn WJ, "Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease", Gut, 53, pp.780~782 (2004)
35. Raman V, "Build-a-bug workshop: using microbial-host interactions and synthetic biology tools to create cancer therapies", Cell Host Microbe, 31, pp.1574~1592 (2023)
36. St Jean AT, "Bacterial delivery of Staphylococcus aureus alpha-hemolysin causes regression and necrosis in murine tumors", Mol. Ther, 22, pp.1266~1274 (2014)
37. Lim D, "Targeted delivery of the mitochondrial target domain of noxa to tumor rissue via synthetic secretion system in E. coli", Front. Bioeng. Biotechnol, 8, pp.840~ (2020)
38. Leventhal DS, "Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity", Nat. Commun, 11, pp.2739~ (2020)
39. Canale FP, "Metabolic modulation of tumours with engineered bacteria for immunotherapy", Nature, 598, pp.662~666 (2021)
40. Chen X, "Surface mineralization of engineered bacterial outer membrane vesicles to enhance tumor photothermal", immunotherapy, 2024, pp.18, 1357~1370
41. An BC, "Colorectal cancer therapy using a Pediococcus pentosaceus SL4 drug delivery system secreting lactic acid bacteria-derived protein p8", Mol. Cells, 42, pp.755~762 (2019)
42. Chung Y, "A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota", Microbiome, 9, pp.122~ (2021)
43. Zhou T, "Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer", NPJ Biofilms Microbiome, 10, pp.6~ (2024)
44. Ho CL, "Engineered commensal microbes for diet-mediated colorectalcancer chemoprevention", Nat. Biomed. Eng, 2, pp.27~37 (2018)
45. Gopalan B, "MDA-7", IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo, 2007, pp.6, 11~
46. Bhutia SK, "mda-7", IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer, 2012, pp.227, 1805~1813
47. Bhutia SK, "Targeting breast cancer-initiating", stem cells with melanoma differentiation-associated gene-7, Int. J. Cancer, pp.2013, 133[DOI]
48. Dash R, "Novel mechanism of MDA-7", IL-24 cancer-specific apoptosis through SARI induction, 2014, pp.74, 563~574
49. Wang L, "Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo", Gene Ther, 24, pp.699~705 (2017)
50. Chowdhury S, "Programmable bacteria induce durable tumor regression and systemic antitumor immunity", Nat. Med, 25, pp.1057~1063 (2019)
51. Gurbatri CR, "Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies", Sci. Transl. Med, 12, pp.eaax0876~ (2020)
52. Gurbatri CR, "Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia", Nat. Commun, 15, pp.646~ (2024)
53. Grundy SM, "Definition of metabolic syndrome : report of the national heart, lung, and blood institute", American heart association conference on scientific issues related to definition, 2004, 109~
54. Wang L, "Engineered Bacteria of MG1363-pMG36e-GLP-1 attenuated obesityinduced by high fat diet in mice", Front. Cell. Infect. Microbiol, 11, pp.595575~ (2021)
55. Torres-Fuentes C, "The microbiota-gut-brain axis in obesity", Lancet Gastroenterol. Hepatol, 2, pp.747~756 (2017)
56. European Association for the Study of the L, "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J. Hepatol, 64, pp.1388~1402 (2016)
57. Rehm J, "Global burden of alcoholic liver diseases", J. Hepatol, 59, pp.160~168 (2013)
58. Wang X, "Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes", Nature, 514, pp.237~241 (2014)
59. Pan CX, "Role of interleukin-22 in liver diseases", Inflamm. Res, 63, pp.519~525 (2014)
60. Oh JH, "Secretion of recombinant interleukin-22 by engineered Lactobacillus reuteri reduces fatty liver disease in a mouse model of diet-induced obesity", mSphere, 5, pp.e0018320~ (2020)
61. Hendrikx T, "Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice", Gut, 68, pp.1504~1515 (2019)
62. Takiishi T, "Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting Lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells", Diabetes, 66, pp.448~459 (2017)
63. Verma A, "Expression of human ACE2 in Lactobacillus and beneficial effects in diabetic retinopathy in mice", Mol. Ther. Methods Clin. Dev, 14, pp.161~170 (2019)
64. Attalla K, "Oxalate content of food : a tangled web", Urology, 84, pp.555~560 (2014)
65. Lubkowicz D, "An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria", Mol. Syst. Biol, 18, pp.e10539~ (2022)
66. Kurtz CB, "An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans", Sci. Transl. Med, 11, pp.eaau7975~ (2019)
67. Isabella VM, "Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria", Nat. Biotechnol, 36, pp.857~864 (2018)
68. Adolfsen KJ, "Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering", Nat. Commun, 12, pp.6215~ (2021)
69. Triassi AJ, "Redesign of an Escherichia coli Nissle treatment for phenylketonuria using insulated genomic landing pads and genetic circuits to reduce burden", Cell Syst, 14, pp.512~524 (2023)
70. Renwick MJ, "A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics", J. Antibiot, 69, pp.73~88 (2016)
71. Fujitani S, "Pneumonia due to Pseudomonas aeruginosa : part I : epidemiology, clinical diagnosis, and source", Chest, 139, pp.909~919 (2011)
72. Saeidi N, "Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen", Mol. Syst. Biol, 7, pp.521~ (2011)
73. Hwang IY, "Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models", Nat. Commun, 8, pp.15028~ (2017)
74. Hwang IY, "Reprogramming microbes to be pathogen-seeking killers", ACS Synth. Biol, 3, pp.228~237 (2014)
75. Ali M, "Updated global burden of cholera in endemic countries", PLoS Negl. Trop. Dis, 9, pp.e0003832~ (2015)
76. Duan F, "Interrupting Vibrio cholerae infection of human epithelial cells with engineered commensal bacterial signaling", Biotechnol. Bioeng, 101, pp.128~134 (2008)
77. Duan F, "Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model", Proc. Natl. Acad. Sci. USA, 107, pp.11260~11264 (2010)
78. Lopez-Igual R, "Engineered toxin-intein antimicrobials can selectively target and kill antibiotic-resistant bacteria in mixed populations", Nat. Biotechnol, 37, pp.755~760 (2019)
79. Jayaraman P, "Repurposing a two-component system-based biosensor for the killing of Vibrio cholerae", ACS Synth. Biol, 6, pp.1403~1415 (2017)
80. Gould LH, "Surveillance for foodborne disease outbreaks-United States, 1998-2008", MMWR Surveill Summ, 62, pp.1~34 (2013)
81. Centers for Disease C, Prevention, "Surveillance for foodborne disease outbreaks--United States, 2009-2010", MMWR Morb. Mortal. Wkly. Rep, 62, pp.41~47 (2013)
82. Forkus B, "Antimicrobial probiotics reduce Salmonella enterica in Turkey gastrointestinal tracts", Sci. Rep, 7, pp.40695~ (2017)
83. Palmer JD, "Engineered probiotic for the inhibition of Salmonella via tetrathionate-induced production of microcin H47", ACS Infect. Dis, 4, pp.39~45 (2018)
84. Ng KM, "Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens", Nature, 502, pp.96~99 (2013)
85. Koh E, "Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism", Nat. Commun, 13, pp.3834~ (2022)
86. Geldart KG, "Engineered E. coli Nissle 1917for the reduction of vancomycin-resistant Enterococcus in the intestinal tract", Bioeng. Transl. Med, 3, pp.197~208 (2018)
87. Tscherner M, "A Synthetic system that senses Candida albicans and inhibits virulence factors", ACS Synth. Biol, 8, pp.434~444 (2019)
88. Ji C, "A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF", Brain Res, 1634, pp.1~11 (2016)
89. Holscher C, "Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases", Biochem. Soc. Trans, 42, pp.593~599 (2014)
90. Ji C, "Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease", Rev. Neurosci, 27, pp.61~70 (2016)
91. Fang X, "Neuroprotective effects of an engineered commensal bacterium in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine Parkinson disease mouse model via producing glucagon-like peptide-1", J. Neurochem, 150, pp.441~452 (2019)
92. Zhang X, "A red light-controlled probiotic bio-system for in-situ gut-brain axis regulation", Biomaterials, 294, pp.122005~ (2023)
93. Cubillos-Ruiz A, "An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis", Nat. Biomed. Eng, 6, pp.910~921 (2022)
94. Bush K, "Epidemiology of beta-Lactamase-producing pathogens", Clin. Microbiol. Rev, 33, pp.e00047-19~ (2020)
95. Pantoja Angles A, "Microbial biocontainment systems for clinical, agricultural, and industrial applications", Front. Bioeng. Biotechnol, 10, pp.830200~ (2022)
96. Lee JW, "Next-generation biocontainment systems for engineered organisms", Nat. Chem. Biol, 14, pp.530~537 (2018)
97. Shen H, "Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy", Nat. Commun, 15, pp.4343~ (2024)
98. Gao Y, "Advances in gut microbiota-targeted therapeutics for metabolic syndrome", Microorganisms, 12, pp.851~ (2024)
99. Inda-Webb ME, "Sub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ", Nature, 620, pp.386~392 (2023)
100. Tang TC, "Hydrogel-based biocontainment of bacteria for continuous sensing and computation", Nat. Chem. Biol, 17, pp.724~731 (2021)
101. Jones TS, "Genetic circuit design automation with Cello 2.0", Nat. Protoc, 17, pp.1097~1113 (2022)
102. Taketani M, "Genetic circuit design automation for the gut resident species Bacteroides thetaiotaomicron", Nat. Biotechnol, 38, pp.962~969 (2020)

관련 논문AI추천